A candidate vaccine designed to protect against chikungunya virus infection has met its primary endpoint in a Phase 3 study paving the way for a regulatory review and possible launch in geographies where the disease is prevalent. The results of the study were published in The Lancet on 12 June 2023. The vaccine, VLA1553, has been developed by Valneva SE of France.
